Payment overview · 2025
General Payments
$666.27
35 reported records · 12 companies
Healthcare provider profile · identity verified
Raul A Rivera, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PASADENA, TX · NPI 1205853843
Verified facts
What the public records show
CMS Open Payments records show Raul A Rivera, MD received $666.27 in general payments during 2025 across 35 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $176.29 | 26.5% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.68 | 15.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $67.33 | 10.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $66.85 | 10.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $66.02 | 9.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.32 | 6.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.08 | 5.1% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $30.00 | 4.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.79 | 4.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.11 | 3.0% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.21 | 2.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.59 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $666.27 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $176.29 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $70.28 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $67.33 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $66.85 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $49.77 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.32 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.08 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $28.79 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $14.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 77 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 165 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
57 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
77 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
165 | 38 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1634 | 530 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 803 | 243 |
| Omeprazole | Omeprazole | 693 | 244 |
| Levothyroxine Sodium | Levothyroxine Sodium | 678 | 197 |
| Metformin Hcl | Metformin Hcl | 625 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 177 |
| Gabapentin | Gabapentin | 538 | 213 |
| Losartan Potassium | Losartan Potassium | 461 | 145 |
| Tamsulosin Hcl | Tamsulosin Hcl | 425 | 143 |
| Nifedipine Er | Nifedipine | 352 | 117 |
| Diclofenac Sodium | Diclofenac Sodium | 348 | 169 |
| Lisinopril | Lisinopril | 343 | 116 |
| Carvedilol | Carvedilol | 327 | 104 |
| Tramadol Hcl | Tramadol Hcl | 310 | 123 |
| Naproxen | Naproxen | 308 | 128 |
| Alendronate Sodium | Alendronate Sodium | 304 | 97 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 263 | 204 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 229 | 73 |
| Furosemide | Furosemide | 219 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 72 |
| Zolpidem Tartrate | Zolpidem Tartrate | 214 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 200 | 63 |
| Glimepiride | Glimepiride | 196 | 68 |
| Irbesartan | Irbesartan | 194 | 57 |
| Ibuprofen | Ibuprofen | 191 | 72 |
| Pioglitazone Hcl | Pioglitazone Hcl | 185 | 63 |
| Alprazolam | Alprazolam | 184 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 58 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 184 | 143 |
| Mirtazapine | Mirtazapine | 178 | 69 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 51 |
| Ozempic | Semaglutide | 165 | 38 |
| Meloxicam | Meloxicam | 152 | 53 |
| Sertraline Hcl | Sertraline Hcl | 148 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 59 |
| Clonidine Hcl | Clonidine Hcl | 138 | 50 |
| Trazodone Hcl | Trazodone Hcl | 138 | 57 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 133 | 40 |
| Eliquis | Apixaban | 128 | 35 |
| Prednisone | Prednisone | 125 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 45 |
| Azithromycin | Azithromycin | 121 | 86 |
| Hydralazine Hcl | Hydralazine Hcl | 114 | 41 |
| Meclizine Hcl | Meclizine Hcl | 114 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 112 | 20 |
| Simvastatin | Simvastatin | 111 | 36 |
| Finasteride | Finasteride | 107 | 43 |
| Donepezil Hcl | Donepezil Hcl | 106 | 40 |
| Nateglinide | Nateglinide | 103 | 38 |
| Baclofen | Baclofen | 102 | 52 |
| Famotidine | Famotidine | 99 | 40 |
| Fenofibrate | Fenofibrate Nanocrystallized | 88 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 34 |
| Sucralfate | Sucralfate | 88 | 40 |
| Jardiance | Empagliflozin | 86 | 33 |
| Enalapril Maleate | Enalapril Maleate | 85 | 28 |
| Lorazepam | Lorazepam | 84 | 21 |
| Clonazepam | Clonazepam | 81 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 32 |
| Allopurinol | Allopurinol | 80 | 25 |
| Acetic Acid | Acetic Acid | 78 | 52 |
| Mounjaro | Tirzepatide | 77 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 69 | 26 |
| Linzess | Linaclotide | 68 | 24 |
| Montelukast Sodium | Montelukast Sodium | 68 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 65 | 32 |
| Oxybutynin Chloride | Oxybutynin Chloride | 62 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 62 | 22 |
| Fenofibrate | Fenofibrate | 61 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 30 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 46 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 54 | 31 |
| Farxiga | Dapagliflozin Propanediol | 53 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 52 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 16 |
| Metformin Hcl Er | Metformin Hcl | 50 | 15 |
| Temazepam | Temazepam | 50 | suppressed |
| Myrbetriq | Mirabegron | 49 | 22 |
| Celecoxib | Celecoxib | 46 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 15 |
| Levemir Flexpen | Insulin Detemir | 45 | 28 |
| Lovastatin | Lovastatin | 45 | 15 |
| Potassium Chloride | Potassium Chloride | 45 | 20 |
| Memantine Hcl | Memantine Hcl | 44 | 17 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 43 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 42 | 16 |
| Januvia | Sitagliptin Phosphate | 42 | 15 |
| Mupirocin | Mupirocin | 41 | 33 |
| Pregabalin | Pregabalin | 41 | 20 |
| Xarelto | Rivaroxaban | 38 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 23 |
| Trulicity | Dulaglutide | 36 | suppressed |
| Clotrimazole | Clotrimazole | 35 | 25 |
| Novolog Flexpen | Insulin Aspart | 35 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 14 |
| Levofloxacin | Levofloxacin | 34 | 33 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 33 | 12 |
| Cephalexin | Cephalexin | 33 | 29 |
| Glipizide | Glipizide | 32 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Spironolactone | Spironolactone | 31 | 13 |
| Desloratadine | Desloratadine | 30 | 13 |
| Methylprednisolone | Methylprednisolone | 30 | 28 |
| Ofloxacin | Ofloxacin | 30 | 24 |
| Atenolol | Atenolol | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 28 | 12 |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 28 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 25 | 20 |
| Latanoprost | Latanoprost | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 11 |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Estradiol | Estradiol | 21 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 20 |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Valsartan | Valsartan | 18 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Xifaxan | Rifaximin | 17 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 14 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 13 |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $666.27 · 35 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, BREZTRI, CRYSVITA, Cologuard Collection Kit, FARXIGA, GEMTESA, Kerendia, MOUNJARO, NEXLETOL, NUZYRA, OTEZLA, Omnipod, Ozempic, REPATHA, TRELEGY ELLIPTA, Wegovy, XHANCE, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error